X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TERN-701 is company’s internally discovered allosteric BCR-ABL tyrosine kinase inhibitor, which is being evaluated for the treatment of chronic myeloid leukemia.
Lead Product(s): TERN-701
Therapeutic Area: Oncology Product Name: TERN-701
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
TERN-601 is an oral, small-molecule glucagon-like peptide-1 receptor, or GLP-1R, agonist program for obesity. Obesity is a chronic disease that is increasing in prevalence in adults, adolescents and children and is often defined by having an elevated BMI of 30 or greater.
Lead Product(s): TERN-601
Therapeutic Area: Nutrition and Weight Loss Product Name: TERN-601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
TERN-701 is Terns’ proprietary, oral, potent, allosteric BCR-ABL TKI specifically targeting the BCR-ABL myristoyl pocket, which is in clinical development for chronic myeloid leukemia.
Lead Product(s): TERN-701
Therapeutic Area: Oncology Product Name: TERN-701
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development for the treatment of NASH.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
TERN-501 is a Thyroid Hormone Receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development.
Lead Product(s): TERN-501
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $86.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 23, 2022
Details:
TERN-501 is a Thyroid Hormone Receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-beta compared to other THR-β agonists in development.
Lead Product(s): TERN-501
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 19, 2022
Details:
TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study.
Lead Product(s): TERN-501,TERN-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Part 1 of AVIATION Trial met primary safety endpoint compared to placebo, for TERN-201, a highly selective, irreversible, covalent inhibitor of VAP-1, administered for 12 weeks to presumed NASH patients was generally well-tolerated with a similar incidence of adverse events.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
